## Most Common Adverse Effect of Calcineurin Inhibitors **Key Point:** Nephrotoxicity is the dose-limiting and most frequent serious adverse effect of both cyclosporine and tacrolimus, occurring in 25–50% of patients on chronic therapy. ### Mechanism of Calcineurin Inhibitor Nephrotoxicity 1. **Acute phase** (reversible): Vasoconstriction of afferent arterioles via reduced nitric oxide and increased endothelin-1 → decreased GFR 2. **Chronic phase** (irreversible): Progressive interstitial fibrosis, tubular atrophy, and arteriolar hyalinosis → permanent renal dysfunction ### Clinical Features | Feature | Details | |---------|----------| | **Onset** | Can occur within weeks to months | | **Pattern** | Dose-dependent; reversible if caught early | | **Monitoring** | Serum creatinine, eGFR every 1–3 months | | **Risk factors** | High drug levels, dehydration, concurrent NSAIDs, older age | | **Management** | Dose reduction, switch to alternative agent (mycophenolate, azathioprine) | **High-Yield:** Cyclosporine causes more hypertension and gingival hyperplasia; tacrolimus causes more hyperglycemia and neurotoxicity — but BOTH cause nephrotoxicity equally. **Clinical Pearl:** Baseline renal function and regular monitoring of serum creatinine are mandatory before and during calcineurin inhibitor therapy. Acute reversible nephrotoxicity can be distinguished from chronic fibrotic changes by renal biopsy or imaging. ### Why Nephrotoxicity Is Most Common Calcineurin inhibitors are used extensively in: - Organ transplantation (renal, cardiac, hepatic) - Autoimmune diseases (SLE, vasculitis, IgA nephropathy) - Long-term exposure in these populations makes nephrotoxicity the dominant dose-limiting toxicity. **Mnemonic — Calcineurin Inhibitor Toxicities (CIT):** **C**ardiovascular (hypertension), **I**nfections (immunosuppression), **T**oxicity (renal, neuro, metabolic) — but renal is #1.
Sign up free to access AI-powered MCQ practice with detailed explanations and adaptive learning.